Compare GSK plc (GSK) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares MBS ETF — how do they compare? GSK plc trades at $46.39 (market cap $91.88B), while iShares MBS ETF trades at $89.59 (market cap $35.41B). The key difference: GSK plc is far larger — about 2.6× iShares MBS ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares MBS ETF for 96 Days on average.
| GSK | MBB | |
|---|---|---|
Market Cap | $91.88B | $35.41B |
Volume | 7,730,529 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $96.91 |
52-Week Low | $43.24 | $89.09 |
Typical Hold Time | 93 Days | 96 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
MBB, the iShares MBS ETF, trades at $89.54, up 0.36% on the day but showing a bearish technical signal overall. The ETF has faced significant short interest growth of 98.3% in September 2026, reaching 6.57 million shares, and recently hit a 52-week low. Recent news highlights concerns over intermediate duration risk amid potential rate hikes, though institutional buying from firms like Corient Private Wealth and Baird Financial Group provides some support. Key technical indicators show oversold conditions on the 12-day RSI but strong selling pressure from moving averages.
The outlook for MBB remains cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. While dividend payments offer income, rising rates and inflation pressures pose downside risks. Analyst sentiment is neutral to bearish, with the ETF's performance heavily tied to Federal Reserve policy. Investors should weigh the high yield against duration risk in a tightening cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
